Common Coexisting Conditions in Ankylosing Spondylitis

IWBCA
Feb 19
9 min read

Ankylosing spondylitis is frequently accompanied by other immune, cardiovascular, bone, mental health, and systemic conditions, with patterns of uveitis, psoriasis, inflammatory bowel disease, cardiometabolic disease, osteoporosis, depression, and several other comorbidities that shape long-term risk and monitoring needs.

Overview

What are the main patterns of coexisting conditions in ankylosing spondylitis?

Ankylosing spondylitis commonly overlaps with a distinct set of immune-mediated conditions and a broader cluster of chronic medical problems, including acute anterior uveitis, psoriasis, and inflammatory bowel disease occur far more often than in the general population. Large cohort and registry studies also show higher rates of cardiovascular disease, hypertension, dyslipidaemia, osteoporosis, vertebral fractures, depression, sleep apnea, fibromyalgia, and several other systemic comorbidities compared with matched controls.

Understanding these patterns helps clinicians target screening and prevention, and helps patients recognize that eye symptoms, bowel changes, skin disease, mood changes, or bone fragility can all be related to the same underlying inflammatory environment rather than being isolated, unrelated problems.

Classic Immune-Related Coexisting Conditions

Which immune-mediated conditions most commonly coexist with ankylosing spondylitis?

The most characteristic coexisting conditions in ankylosing spondylitis are extra-articular immune manifestations that define the broader spondyloarthritis spectrum. Across meta-analyses and national registry cohorts, acute anterior uveitis, psoriasis, and inflammatory bowel disease exhibit the highest enrichment relative to the background population. All three share genetic and immunologic pathways with ankylosing spondylitis, including strong associations with HLA-B27 and cytokine networks involving TNF and the IL-23/IL-17 axis. They may appear years before, at the same time as, or after the onset of axial symptoms, and their presence significantly increases the likelihood that back pain and stiffness reflect an axial spondyloarthritis process rather than a mechanical disorder.

Acute Anterior Uveitis (Eye Inflammation): Acute anterior uveitis is the single most typical extra-articular manifestation of ankylosing spondylitis. Pooled data from large observational series indicate that approximately one quarter of people with ankylosing spondylitis will experience at least one episode of uveitis during their lifetime, and a meaningful subset will have recurrent attacks. Episodes typically present with unilateral redness of the eye, deep, aching pain, light sensitivity, and blurred or hazy vision that develops over hours to a few days rather than gradually. The classic pattern is acute, anterior, and nongranulomatous, and HLA-B27 positivity is common among affected individuals. Uveitis may precede spinal symptoms by several years, may occur during periods of active axial disease, or may flare independently of back pain. Without prompt ophthalmologic evaluation and intensive topical therapy, inflammation can cause synechiae, secondary glaucoma, cataract, band keratopathy, and permanent vision loss. In patients with frequent or severe attacks, systemic therapy for underlying spondyloarthritis, particularly biologic agents targeting TNF or IL-17, can reduce uveitis recurrence and should be considered in joint decision-making with ophthalmology.

Psoriasis (Inflammatory Skin Disease): Psoriasis occurs at clearly increased rates in ankylosing spondylitis compared with the general population. Meta-analytic estimates place its prevalence close to 8 to 10 percent in clinical ankylosing spondylitis cohorts, although administrative datasets may underreport dermatologic diagnoses while still confirming a higher rate than matched controls. Cutaneous findings range from classic, sharply demarcated plaques on the scalp, elbows, knees, umbilicus, or gluteal cleft to smaller, scattered lesions that are easy to overlook. Nail involvement is common and may include pitting, onycholysis, subungual hyperkeratosis, or longitudinal ridging, even when skin plaques are minimal. In some individuals, psoriasis precedes inflammatory back pain and may be misdiagnosed as an isolated skin disease until axial symptoms emerge. The presence of psoriasis does not alter the classification of axial involvement as ankylosing spondylitis or axial psoriatic arthritis in clinical practice, but it has important implications for treatment selection. Certain TNF inhibitors, IL-17 inhibitors, and IL-23 pathway agents have strong efficacy for both spine inflammation and skin disease, whereas others have more limited dermatologic benefit. Therapy that controls spinal symptoms while leaving psoriasis active, or therapy that improves skin but aggravates coexisting inflammatory bowel disease, may be considered suboptimal in this context.

Inflammatory Bowel Disease (Crohn Disease and Ulcerative Colitis): Crohn disease and ulcerative colitis are approximately 2 to 3 times more common in ankylosing spondylitis than in the general population, with pooled prevalence estimates of 6 to 7 percent in established cohorts and incident rates clearly higher than in matched controls. Inflammatory bowel disease can present with chronic or recurrent diarrhea, abdominal cramping, unintentional weight loss, urgency, nocturnal stools, and episodic rectal bleeding. Extraintestinal signs, such as perianal fistulae, fissures, or iron-deficiency anemia, may be the initial clues in some patients. Importantly, a substantial proportion of people with ankylosing spondylitis exhibit microscopic intestinal inflammation on endoscopy or biopsy despite having no overt gastrointestinal symptoms, and this subclinical gut involvement correlates with systemic inflammatory burden and future risk of overt inflammatory bowel disease. Bowel disease can precede axial symptoms, co-occur with them, or arise later in the disease course. Its presence directly influences medication strategy. Monoclonal TNF inhibitors with gut indications can simultaneously treat spine inflammation and inflammatory bowel disease, while some IL-17 inhibitors carry a documented risk of provoking or worsening bowel inflammation and are generally avoided in patients with established Crohn disease or ulcerative colitis. Systematic inquiry into bowel habits, stool caliber, perianal symptoms, and weight changes, along with a low threshold for gastroenterology referral when red flags are present, is integral to comprehensive ankylosing spondylitis care.

Cardiometabolic Comorbidities

How common are cardiovascular and metabolic conditions in ankylosing spondylitis?

Beyond classic immune manifestations, people with ankylosing spondylitis experience a significant burden of cardiovascular disease and traditional risk factors. Systemic inflammation, altered body composition, reduced physical activity from pain and stiffness, and medication exposures all contribute to higher rates of hypertension, dyslipidaemia, ischemic heart disease, and related conditions.

Hypertension and Atherosclerotic Disease: Large administrative datasets show that approximately one-third of patients with ankylosing spondylitis have a recorded cardiovascular diagnosis at baseline, including hypertension in roughly 30 percent and measurable rates of coronary artery disease, atherosclerosis, stroke, and myocardial infarction that exceed those of matched controls. Follow-up analyses indicate a sustained increase in incident cardiovascular events, with hazard ratios typically around 1.3-1.5 relative to populations without AS. This pattern supports proactive management of blood pressure, lipids, smoking, and physical activity.

Metabolic Risk Factors (Hyperlipidaemia and Obesity): Meta-analyses in axial spondyloarthritis report hyperlipidaemia in approximately one sixth of patients and obesity in approximately one seventh, with both conditions more frequent than in non-SpA controls. These risk factors interact with chronic inflammation to accelerate atherosclerotic disease. Routine lipid screening, weight counseling, and lifestyle interventions are therefore integral parts of ankylosing spondylitis care, not separate, optional concerns.

Venous Thromboembolism (Blood Clots): Population-based cohorts indicate that venous thromboembolism, including deep vein thrombosis and pulmonary embolism, occurs modestly but significantly more often in ankylosing spondylitis than in matched controls, with roughly double the incidence in some analyses. Risk appears to reflect the combination of systemic inflammation, reduced mobility during flares, and overlapping cardiovascular risk profiles. Awareness of this elevated baseline risk is important when additional prothrombotic factors are present.

Structural Cardiac and Aortic Involvement: Long-standing ankylosing spondylitis can also involve the aortic root, aortic valve, and cardiac conduction system, leading to aortic regurgitation, conduction blocks, and cardiomyopathy in a minority of patients, particularly those with long disease duration. These manifestations are much less common than general cardiovascular risk factors but warrant consideration in patients with long-term AS who present with syncope, exertional dyspnea, new murmurs, or arrhythmias.

Bone Health and Fracture Risk

Why are osteoporosis and fractures so important in ankylosing spondylitis?

Ankylosing spondylitis combines chronic systemic inflammation, altered spinal biomechanics, and, in some cases, long-term glucocorticoid exposure. This combination leads to a paradoxical situation in which the spine becomes more rigid and structurally fused while the underlying vertebral bone may be osteoporotic, increasing the risk of vertebral compression and traumatic fractures.

Osteoporosis and Low Bone Density: Claims-based analyses and observational cohorts consistently show higher rates of osteoporosis in ankylosing spondylitis than in matched controls, with some large datasets reporting baseline osteoporosis in approximately 4 percent of AS patients and incident osteoporosis occurring three to four times more frequently over follow-up. Lower bone density can be present early in the disease course, including in younger patients, and correlates with inflammation and reduced mobility rather than age alone.
Vertebral and Other Fragility Fractures: Vertebral fractures are particularly important in ankylosing spondylitis because spinal fusion and kyphosis increase mechanical stress and make fractures more difficult to detect on standard radiographs. Claims data indicate spinal fractures at baseline and during follow-up are several times more common in AS than in controls. Even relatively minor trauma can cause serious injury in a rigid spine, including unstable fractures and neurologic compromise. Proactive bone density testing, vitamin D optimization, avoidance of unnecessary glucocorticoids, and early use of anti-osteoporotic therapies when indicated are central to fracture prevention.

Mental Health and Pain-Amplification Conditions

How often do depression and fibromyalgia coexist with ankylosing spondylitis?

Chronic inflammatory pain, sleep disruption, functional limitations, and uncertainty about the future all influence mental health in ankylosing spondylitis. Epidemiologic data show a clear excess burden of mood disorders and pain-amplification syndromes such as fibromyalgia in this population.

Depression and Anxiety: Large administrative cohorts report depression diagnoses in roughly 10 to 11 percent of patients with ankylosing spondylitis at baseline, compared with about 6 percent of matched controls, with incident depression almost doubling during follow-up. Meta-analyses across axial spondyloarthritis indicate that depression is strongly associated with higher reported disease activity, greater pain, more fatigue, and lower quality of life. Anxiety disorders follow similar patterns, though they are less consistently captured in claims data. Recognition and treatment of depression are therefore not ancillary; they are central to overall disease control and patient-reported outcomes.
Fibromyalgia and Central Sensitization: Population-based studies indicate that fibromyalgia is more frequent in ankylosing spondylitis than in the general population, with hazard ratios around 1.3 in some national cohorts. People may report widespread pain, fatigue, non-restorative sleep, and cognitive complaints that are out of proportion to objective inflammatory findings. Coexisting fibromyalgia can inflate disease activity scores and make it harder to judge the efficacy of anti-inflammatory therapies. Structured pain assessment, attention to sleep and mood, graded exercise, and multimodal pain management can help disentangle persistent inflammation from pain amplification.

Other Systemic Comorbidities

Which additional systemic conditions are more common in ankylosing spondylitis?

Beyond classic spondyloarthritis manifestations, ankylosing spondylitis is associated with a spectrum of other medical conditions whose prevalence exceeds that of matched general population cohorts. These comorbidities affect respiratory health, renal function, gastrointestinal tract integrity, sleep, and overall cancer risk.

Sleep Apnea and Respiratory Conditions: Obstructive sleep apnea is more prevalent in ankylosing spondylitis than in the general population, with some claims analyses reporting baseline rates of approximately 9 percent, compared with about 5 percent in controls, and a higher incidence over time. Asthma also occurs more frequently. In addition, long-standing AS can lead to restrictive lung physiology and upper-lobe fibrobullous changes, which may present with exertional dyspnea and reduced exercise capacity even without classic obstructive disease. These patterns support a low threshold for sleep and pulmonary evaluation when symptoms arise.
Renal Disease and Amyloidosis: IgA nephropathy, chronic kidney disease, and secondary amyloidosis are recognized but relatively uncommon renal complications of ankylosing spondylitis. Persistent systemic inflammation and, in some cases, long-term nonsteroidal anti-inflammatory drug use can contribute to renal injury. Periodic monitoring of serum creatinine, estimated glomerular filtration rate, and urinalysis is therefore recommended, especially in patients with long disease duration or additional nephrotoxic exposures.
Gastrointestinal Ulcers and Medication-Related Complications: Gastrointestinal ulcers and bleeding are more common in ankylosing spondylitis than in matched controls, in part due to cumulative exposure to nonsteroidal anti-inflammatory drugs used for pain and stiffness. Large cohorts have documented roughly double the incidence of documented gastrointestinal ulcers in AS versus controls. Gastroprotective strategies, regular reassessment of NSAID dosing, and prompt evaluation of alarm symptoms such as melena, weight loss, or persistent epigastric pain are important preventive measures.
Malignancy: Overall malignancy rates in ankylosing spondylitis are modestly elevated in some cohorts, particularly in individuals under 65, but not to the extent seen in certain connective tissue diseases with strong cancer-associated autoantibodies. Specific cancer patterns vary between studies, and part of the signal may relate to shared risk factors such as smoking and chronic inflammation. Routine age-appropriate cancer screening remains the primary strategy, with individualized adjustments for particular drug exposures or family history.

Clinical Implications and Monitoring

How should coexisting conditions shape management in ankylosing spondylitis?

The comorbidity profile in ankylosing spondylitis has direct implications for assessment, monitoring, and treatment selection. Uveitis, psoriasis, and inflammatory bowel disease require early recognition and coordinated care with ophthalmology, dermatology, and gastroenterology. Cardiovascular risk factors call for systematic screening, lifestyle intervention, and aggressive risk modification. Bone health, mental health, sleep, renal function, and gastrointestinal integrity all require proactive, longitudinal monitoring.

For patients, this means that new or seemingly unrelated symptoms, such as unilateral red eye, persistent diarrhea, a new rash, unexplained chest pain, shortness of breath, a low-impact fracture, or a marked change in mood, should be reported and taken seriously. For clinicians, a structured comorbidity review at regular intervals can help catch these overlapping conditions early, align treatment choices with the broader risk profile, and reduce long-term complications across the full spectrum of ankylosing spondylitis.

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider with any questions about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.